Compare Bayer AG with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 1.21% and Operating profit at -6.41% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 37,588 Million ()
15.00
NA
0.00%
1.22
9.71%
1.45
Revenue and Profits:
Net Sales:
11,438 Million
(Quarterly Results - Dec 2025)
Net Profit:
-3,750 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.46%
0%
6.46%
6 Months
40.4%
0%
40.4%
1 Year
68.77%
0%
68.77%
2 Years
34.62%
0%
34.62%
3 Years
-31.68%
0%
-31.68%
4 Years
-36.89%
0%
-36.89%
5 Years
-28.1%
0%
-28.1%
Bayer AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.94%
EBIT Growth (5y)
177.58%
EBIT to Interest (avg)
2.34
Debt to EBITDA (avg)
3.73
Net Debt to Equity (avg)
1.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
5.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
8.66%
ROE (avg)
15.91%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.46
EV to EBIT
9.61
EV to EBITDA
6.85
EV to Capital Employed
1.22
EV to Sales
1.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.70%
ROE (Latest)
9.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
11,438.00
11,729.00
-2.48%
Operating Profit (PBDIT) excl Other Income
2,036.00
1,289.00
57.95%
Interest
675.00
703.00
-3.98%
Exceptional Items
-3,675.00
-790.00
-365.19%
Consolidate Net Profit
-3,750.00
-328.00
-1,043.29%
Operating Profit Margin (Excl OI)
148.80%
40.80%
10.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -2.48% vs -1.12% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -1,043.29% vs -124.44% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
45,575.00
46,606.00
-2.21%
Operating Profit (PBDIT) excl Other Income
11,009.00
8,529.00
29.08%
Interest
1,722.00
1,959.00
-12.10%
Exceptional Items
-6,413.00
-6,368.00
-0.71%
Consolidate Net Profit
-3,595.00
-2,546.00
-41.20%
Operating Profit Margin (Excl OI)
152.60%
96.10%
5.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.21% vs -2.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -41.20% vs 13.46% in Dec 2024
About Bayer AG 
Bayer AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






